Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.62 |
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | DRD3 | P35462 | 8/20 | 0.62 |
| ▸ | DRD5 | P21918 | 8/20 | 0.62 |
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028084 | 1.00 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30299229 | 0.95 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL577378 | 0.95 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL4133301 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30888625 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL20231604 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL2607471 | 0.91 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| Methylene Chloride SCHEMBL29094368 | 0.88 | DRD1 (0.55) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL12077890 | 0.84 | DRD1 (0.51) | DRD1DRD2DRD3DRD5DRD4 | |
| Propylamine SCHEMBL9435187 | 0.83 | DRD2 (0.51) | DRD1DRD2DRD3DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490388-A | Method for separating and obtaining phenolic substances from phenol-containing coal tar | 煤炭科学技术研究院有限公司 | 2025-02-21 | — | — | CN | claimed |
| EP-0674232-B1 | Recording sheets | XEROX CORP (US) | 2000-05-31 | — | — | EP | claimed |
| US-5663022-A | Recording sheets | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0674232-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-5451466-A | Electrophotographic use, reduced heat and energy required for toner fusion, styrene copolymer, indan or derivative | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| EP-4453129-B1 | ELECTRONIC DEVICES | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-02-04 | — | — | EP | disclosed |
| US-12484440-B2 | Electroluminescent devices having sensitizer and fluorescent emitter | MERCK PATENT GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12421178-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-09-23 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250081832-A1 | METHOD FOR FORMING AN ORGANIC ELEMENT OF AN ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2025-03-06 | — | — | US | disclosed |
| EP-0275104-A2 | Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor | FERRER INTERNACIONAL, S.A. (ES) | 1988-07-20 | — | — | EP | disclosed |
| EP-0207889-A1 | Process for the preparation of metallocene complexes | CIBA-GEIGY AG (CH) | 1987-01-07 | — | — | EP | disclosed |
| EP-0088345-B1 | 2-AMINOMETHYL-6-SULFAMOYLPHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-17 | — | — | EP | disclosed |
| US-4607030-A | ANTIEDEMICS, HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0088346-B1 | 2-AMINOMETHYL-PHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088346-A2 | 2-Aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0020301-A1 | Basically substituted phenols, process for their preparation, pharmaceutical preparations containing these compounds and their use | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | DRD1 74/4885DRD2 44/4885DRD3 100/4885 |
| US-12421178-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | NAT1, AADAC, ARNT | DRD1 1560/4885DRD2 2225/4885DRD3 2413/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | DRD1 2070/4885DRD2 2503/4885DRD3 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.